|
|
||||||||
DEVELOPMENTAL PHYSIOLOGY AND PREGNANCY
1Mount Sinai Hospital, Toronto; Departments of 2Obstetrics and Gynecology and 3Physiology, University of Toronto, Toronto, Ontario, Canada; and 4New Jersey Medical School, Newark, New Jersey
Submitted 10 November 2005 ; accepted in final form 13 April 2006
Elevated expression of soluble vascular endothelial growth factor receptor-1 (sFlt-1) in preeclampsia plays a major role in the pathogenesis of this serious disorder of human pregnancy. Although reduced placental oxygenation is thought to be involved in the pathogenesis of preeclampsia, it is unclear how oxygen regulates placental sFlt-1 expression. The aims herein were to investigate sFlt-1 expression in in vivo and in vitro physiological and pathological models of human placental hypoxia and to understand the role of hypoxia inducible factor-1 (HIF-1) in regulating the expression of this molecule. sFlt-1 expression in placental villi was significantly increased under physiological low oxygen conditions in early first-trimester and in high-altitude placentae, as well as in pathological low oxygen conditions, such as preeclampsia. In high-altitude and in preeclamptic tissue, sFlt-1 localized within villi to perivascular regions, the syncytiotrophoblast layer, and syncytial knots. In first-trimester villous explants, low oxygen, but not hypoxia-reoxygenation (HR), increased sFlt-1 expression. Moreover, exposure of villous explants to dimethyloxalyl-glycin, a pharmacological inhibitor of prolyl-hydroxylases, which mimics hypoxia by increasing HIF-1
stability, increased sFlt-1 expression. Conversely, HIF-1
knockdown using antisense oligonucleotides, decreased sFlt-1 expression. In conclusion, placental sFlt-1 expression is increased by both physiologically and pathologically low levels of oxygen. This oxygen-induced effect is mediated via the transcription factor HIF-1. Low oxygen levels, as opposed to intermittent oxygen tension (HR) changes, play an important role in regulating sFlt-1 expression in the developing human placenta and hence may contribute to the development of preeclampsia.
hypoxia; hypoxia-reoxygenation; high altitude; preeclampsia
This article has been cited by other articles:
![]() |
J. Hasan, K. D. Beharry, A. M. Valencia, A. Strauss, and H. D. Modanlou Soluble Vascular Endothelial Growth Factor Receptor 1 in Tracheal Aspirate Fluid of Preterm Neonates at Birth May Be Predictive of Bronchopulmonary Dysplasia/Chronic Lung Disease Pediatrics, June 1, 2009; 123(6): 1541 - 1547. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Herse, S. Verlohren, K. Wenzel, J. Pape, D. N. Muller, S. Modrow, G. Wallukat, F. C. Luft, C. W.G. Redman, and R. Dechend Prevalence of Agonistic Autoantibodies Against the Angiotensin II Type 1 Receptor and Soluble fms-Like Tyrosine Kinase 1 in a Gestational Age-Matched Case Study Hypertension, February 1, 2009; 53(2): 393 - 398. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Karumanchi and M. D. Lindheimer Preeclampsia Pathogenesis: "Triple A Rating"-Autoantibodies and AntiAngiogenic Factors Hypertension, April 1, 2008; 51(4): 991 - 992. [Full Text] [PDF] |
||||
![]() |
C. C. Zhou, S. Ahmad, T. Mi, S. Abbasi, L. Xia, M.-C. Day, S. M. Ramin, A. Ahmed, R. E. Kellems, and Y. Xia Autoantibody From Women With Preeclampsia Induces Soluble Fms-Like Tyrosine Kinase-1 Production via Angiotensin Type 1 Receptor and Calcineurin/Nuclear Factor of Activated T-Cells Signaling Hypertension, April 1, 2008; 51(4): 1010 - 1019. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Gilbert, M. J. Ryan, B. B. LaMarca, M. Sedeek, S. R. Murphy, and J. P. Granger Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H541 - H550. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Gilbert, S. A. Babcock, and J. P. Granger Hypertension Produced by Reduced Uterine Perfusion in Pregnant Rats Is Associated With Increased Soluble Fms-Like Tyrosine Kinase-1 Expression Hypertension, December 1, 2007; 50(6): 1142 - 1147. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hattori, S. Yamamoto, and N. Matsuda Sympathetic Control of VEGF Angiogenic Signaling: Dual Regulations by {alpha}2-Adrenoceptor Activation? Circ. Res., September 28, 2007; 101(7): 642 - 644. [Full Text] [PDF] |
||||
![]() |
A. Rajakumar, A. Jeyabalan, N. Markovic, R. Ness, C. Gilmour, and K. P. Conrad Placental HIF-1{alpha}, HIF-2{alpha}, membrane and soluble VEGF receptor-1 proteins are not increased in normotensive pregnancies complicated by late-onset intrauterine growth restriction Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R766 - R774. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hladunewich, S. A. Karumanchi, and R. Lafayette Pathophysiology of the Clinical Manifestations of Preeclampsia Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 543 - 549. [Full Text] [PDF] |
||||
![]() |
C. A. Hubel, G. Wallukat, M. Wolf, F. Herse, A. Rajakumar, J. M. Roberts, N. Markovic, R. Thadhani, F. C. Luft, and R. Dechend Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia Hypertension, March 1, 2007; 49(3): 612 - 617. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ietta, Y. Wu, R. Romagnoli, N. Soleymanlou, B. Orsini, S. Zamudio, L. Paulesu, and I. Caniggia Oxygen regulation of macrophage migration inhibitory factor in human placenta Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E272 - E280. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |